Fed. Circ. Casts Doubt On Novartis MS Drug PTAB Win
By Britain Eakin ( January 9, 2020, 7:30 PM EST) -- A Federal Circuit panel appeared skeptical Thursday of Novartis' argument that the written description of a patent covering multiple sclerosis drug Gilenya doesn't need to explicitly say the treatment excludes a loading dose prior to starting a daily dose regimen....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.